CommercialCoverageMedium impact
Ryzneuta (efbemalenograstim alfa-vuxw)
Blue Cross & Blue Shield of Mississippi·MS · Oncology, Hematology·Medical Policy
Effective date
Oct 15, 2025
We identified it
Jun 20, 2026
Summary
BCBS Mississippi has added a new policy designating Ryzneuta (efbemalenograstim alfa-vuxw) as not medically necessary, citing other covered alternatives for preventing chemotherapy-induced febrile neutropenia. Claims for this medication and its administration will be denied without prior authorization approval.
Action Required
Immediately: Billing team must update systems to flag HCPCS code J9361 (Ryzneuta injection) as requiring prior authorization through BCBSMS PA review process before billing. Notify oncology providers that this medication is considered not medically necessary and alternative covered options should be used. Claims for J9361 without prior auth approval will be denied.